S100A7 (Psoriasin), highly expressed in Ductal Carcinoma In Situ (DCIS), is regulated by IFN-gamma in mammary epithelial cells by Petersson, Stina et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
BMC Cancer
Open Access Research article
S100A7 (Psoriasin), highly expressed in Ductal Carcinoma In Situ 
(DCIS), is regulated by IFN-gamma in mammary epithelial cells
Stina Petersson1, Anna Bylander1, Maria Yhr1 and Charlotta Enerbäck*1,2
Address: 1Department of Clinical Genetics, Sahlgrenska University Hospital, SE-413 45 Göteborg, Sweden and 2Department of Dermatology, 
Sahlgrenska University Hospital, SE-413 45 Göteborg, Sweden
Email: Stina Petersson - stina.petersson@clingen.gu.se; Anna Bylander - anna.bylander@clingen.gu.se; Maria Yhr - maria.yhr@clingen.gu.se; 
Charlotta Enerbäck* - Charlotta.enerback@clingen.gu.se
* Corresponding author    
Abstract
Background: The aim of the present work was to explore signal transduction pathways used in
the regulation of S100A7 (psoriasin). Members of the S100 gene family participate in many
important cellular functions. Psoriasin, S100A8 (calgranulin A) and S100A9 (calgranulin B) are
expressed in ductal carcinoma in situ (DCIS), as well as in the hyperproliferative skin disease,
psoriasis. In the latter condition, a disturbance in the STAT pathway has recently been reported.
This pathway is implicated in the regulation of IFN-gamma, widely recognized as a key cytokine in
psoriasis. IFN-gamma also exerts anti-tumor action in a number of tumor cell types, including
breast cancer. We therefore examined the effect of IFN-gamma and STAT-signaling on the
psoriasin expression.
Methods: We established a TAC2 mouse mammary epithelial cell line with tetracycline-inducible
psoriasin expression (Tet-Off). Viability in cell culture was estimated using MTS assay. Protein and
gene expression were evaluated by Western blotting and quantitative real-time PCR. Statistical
analyses were assessed using a one-tailed, paired t-test.
Results: We report the downregulation of psoriasin by IFN-gamma in the MDA-MB-468 breast
cancer cell line, as well as the downregulation of psoriasin induced by anoikis in cell lines derived
from different epithelial tissues. In contrast, IFN-gamma had no suppressive effect on calgranulin A
or calgranulin B. IFN-gamma is an important activator of the STAT1 pathway and we confirmed an
active signaling pathway in the cell lines that responded to IFN-gamma treatment. In contrast, in
the SUM190 breast carcinoma cell line, IFN-gamma did not suppress the expression of endogenous
psoriasin. Moreover, a reduced phosphorylation of the STAT1 protein was observed. We showed
that IFN-gamma treatment and the inhibition of the transcription factor NFkappaB had a synergistic
effect on psoriasin levels. Finally, in TAC2 cells with tetracycline-induced psoriasin expression, we
observed the increased viability of psoriasin-expressing cells after IFN-gamma treatment.
Conclusion:  Our data support the possibility that psoriasin expression is transcriptionally
suppressed by IFN-gamma and that this effect is likely to be mediated by the activation of the
STAT1 signaling pathway. The increased viability of psoriasin-expressing cells after IFN-gamma
exposure suggests that psoriasin expression leads to the development of an apoptosis-resistant
phenotype.
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Background
S100 proteins are characterised by calcium-binding
domains and they are involved in many cellular processes
such as proliferation, differentiation and cell shape [1].
Three proteins in this family, predominantly psoriasin but
also calgranulin A and calgranulin B, have been shown to
be highly expressed in DCIS [2-4]. Both we and others
have also identified psoriasin as being differentially
expressed between DCIS and invasive breast carcinomas
and have found a correlation to poor prognosis, suggest-
ing its potential involvement in tumour progression [3-6].
Psoriasin protein was detected in the cytoplasm and the
nucleus, but it was also found to be secreted [2,3]. In
MCF10A human immortalised mammary epithelial cells,
the expression of psoriasin is very low in exponentially
growing cells, but it is significantly upregulated by growth
factor deprivation, loss of attachment to the extracellular
matrix (anoikis), and confluent conditions [3]. Moreover,
we showed that psoriasin was induced by reactive oxygen
species (ROS) [7]. Since all these conditions influence cell
proliferation and survival, psoriasin may play a role in the
regulation of these pathways. Consequently, psoriasin
expression was shown to correlate to increased survival
and NFκB signaling [7,8]. Moreover, psoriasin was found
to interact with Jun activating binding protein1 (Jab1),
which is involved in multiple signal transduction path-
ways, including the regulation of JUN/AP1 transcription
factors [6]. The over expression of psoriasin in MDA-MB-
231 breast cancer cells was shown to increase nuclear Jab1
activity and enhance tumorigenesis in vivo in nude mice
[6]. We recently showed that the downregulation of
endogenous psoriasin expression in the MDA-MB-468
cell line by short hairpin RNAs increased cell migration
and invasion without influencing cell proliferation and
survival in vitro but inhibited tumour growth in vivo. In
accordance with these findings, we showed an upregula-
tion of matrix metalloproteinase 13 (MMP13) and a
downregulation of vascular endothelial growth factor
(VEGF) in cells with reduced psoriasin levels [9].
There is evidence that psoriasin can function as a chemo-
tactic factor for CD4+ lymphocytes in the skin and it has
recently been implicated in the anti-bacterial defence
mechanism of the skin [10,11]. The high expression of
psoriasin and calgranulin B was initially observed in pso-
riasis [12,13], which is characterised by the hyperprolifer-
ation of keratinocytes, the infiltration of activated T
lymphocytes and vascular neogenesis [14], features it
shares with neoplastic tissues. Psoriasis is a T-cell-medi-
ated disorder and the production of proinflammatory
cytokines like Interferon-gamma (IFN-gamma), Inter-
leukin-1 and Interleukin-12 plays an important role in the
psoriatic phenotype. IFN-gamma is one of the key
cytokines in psoriasis and is present at high levels in the
psoriatic lesion. Its involvement in the pathogenesis of
psoriasis is suggested by the finding that uninvolved pso-
riatic skin develops psoriasis-like lesions at the site of IFN-
gamma injection [15].
IFN-gamma has also demonstrated anti-tumor action in
diverse tumor cell types [16]. IFN-gamma was shown to
inhibit the cell growth of mammary carcinoma cells and
also to reduce angiogenesis [17,18]. The characterization
of genes that are regulated by IFN-gamma may lead to a
better understanding of the anti-tumoral mechanisms.
The purpose of this study was therefore to examine the
expression of the S100 proteins psoriasin, calgranulin A
and calgranulin B in mammary epithelial cells and kerati-
nocytes in vitro after IFN-gamma treatment, with the aim
of elucidating signal transduction pathways relevant for
both DCIS and psoriasis. We report the suppression of
psoriasin by IFN-gamma in mammary epithelial cells and
in keratinocytes by the activation of the signal transducers
and activators of transcription 1 (STAT1) signaling path-
way.
Methods
Cell lines and culture condition
The primary human keratinocyte cell line, HEKn, was cul-
tured in Epilife medium, supplemented with 1% EDGS
and 0. 1% calcium chloride (CaCl2) (Cascade Biologics™,
Portland, OR, USA). The MDA-MB-468 (mammary breast
carcinoma) and MCF10A (immortalised normal breast
epithelium) cell lines were obtained from American Type
Culture Collection and were cultivated in 10% foetal
clone III in McCoy's 5A medium (Gibco, Invitrogen Cor-
poration, UK) and in DMEM/F12 medium (PAA Labora-
tories GmbH, Pasching, Austria), supplemented with 20
ng/ml epidermal growth factor, 100 ng/ml cholera toxin,
0,01 mg/ml insulin and 500 ng/ml hydrocortisone. The
SUM190 cell line (Asterand, Detroit, MI) was cultured in
Mammary Epithelial Cell Medium MEGM BulletKit® (cc-
3150) (Cambrex Bio Science Walkersville, Inc.). TAC2
(mammary mouse epithelial cells), kindly provided by
Professor R. Montesano, was cultured in 10% FBS in
DMEM/high glucose medium (Life Technologies, Inc.),
supplemented with 20 ng/ml tetracycline, 100 ng/ml
hygromycin and 250 µg/ml neomycin. For suspension
cultures (anoikis), cells were plated into poly-2-hydroxy-
ethylmethacrylate (polyHEMA) (Sigma Aldrich, Sweden)
coated (10 mg/cm2 in 95% ethanol) Petri dishes. To inves-
tigate the regulation of endogenous psoriasin expression
in the MDA-MB-468 cell line, SUM190 cell line and pso-
riasin induced by anoikis in HEKn and MCF10A, IFN-
gamma (Sigma-Aldrich, Sweden) was added to the
medium at a concentration of 250–2000 u/ml medium.
To examine the effect of the NFκB pathway, MCF10A cells
were plated in polyHEMA-coated Petri dishes and infected
with 1 µl Green Fluorescent Protein (GFP) or phosphor-
ylation-defective dnIkkβ adenovirus. Adenovirus genera-BMC Cancer 2007, 7:205 http://www.biomedcentral.com/1471-2407/7/205
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tion were as previously described [7]. After the indicated
time, cells were harvested and immediately frozen in liq-
uid nitrogen. In experiments performed using hydrogen
peroxide (H2O2) (Sigma Aldrich, Sweden), cells were
plated and treated the next day with 75 µM H2O2 for one
hour. Cells were harvested after 48 h in regular medium.
Establishment of tetracycline-inducible psoriasin 
expression in a TAC2 mouse mammary epithelial cell line
TAC2 cells were kindly provided by Professor R Monte-
sano. We established a cell line expressing the Tet activator
(tTA) by transfecting TAC2 cells with the ptTA-IRES-Neo
(tTA, tet activator; IRES, internal ribosomal entry; neo,
G418 resistance gene) plasmid, selected for neomycin-
resistant clones. Next, we subcloned the psoriasin cDNA
into pBI-EGFP2. Cells with a high expression of tTA were
transfected with the pBI-EGFP-psoriasin plasmid and
clones with low background expression and homogene-
ous psoriasin induction were selected.
Western blotting
Protein concentrations were determined using the Bio-
Rad protein assay (Bio-Rad, Hercules, CA, USA) and a spe-
cific amount of protein lysate was run on a Nu PAGE™ 4–
12% Bis-Tris Gel (Invitrogen™, Sweden) for one hour,
together with 10 µl of MultiMark® (Invitrogen™, Sweden).
Proteins were then transferred by blotting to a 140 µm
nitrocellulose blotting membrane at 30 V for 1.5 hours in
1× NuPAGE™ transfer buffer (Invitrogen™, Sweden). The
membrane was then blocked in 5% skimmed milk pow-
der in Tris-buffered saline-0.05% Tween (1× TBST-buffer)
over night. Western blot analyses of cell lysate were pro-
duced with anti-psoriasin (mouse-Ab) (Imgenex, San
Diego, CA, USA), anti-tubulin β (mouse-Ab) (Neomark-
ers, Freemont, CA, USA), anti-Stat1α (mouse-Ab), anti-p-
Stat1 (rabbit-Ab), anti-calgranulin A (mouse-Ab), anti-
Caspase-3 (mouse-Ab) and anti-GAPDH (rabbit-Ab)
(Santa Cruz Biotechnology, USA). Moreover, anti-calgran-
ulin B (mouse-Ab) (Dianova GmbH, Hamburg, Ger-
many) and anti-IκB-α (mouse-Ab) (Cell Signaling
Technology, USA) were used. Horseradish-peroxidase-
conjugated AffiniPure anti-mouse or anti-rabbit (Jackson
ImmunoResearch, West Grove, PA, USA) served as sec-
ondary antibodies, followed by incubation in SuperSig-
nal® Stable Peroxide Solution together with SuperSignal®
West Pico Luminol/Enhancer Solution (Pierce, Rockford,
IL, USA), according to the manufacturer's description. The
chemiluminescence signal was registered with a
FluorChem 8000 camera (Alpha Innotech, San Leandro,
CA, USA).
RNA extraction, cDNA synthesis and quantitative real-
time PCR
Total RNA was prepared from cultured cells using an RNe-
asy® Mini Kit (Qiagen, Maryland, USA), according to the
manufacturer's protocol. cDNA was synthesised using
SuperScript™II RNase H- Reverse Transcriptase (Invitro-
gen™, Sweden), as described by the manufacturer. The rel-
ative expression of psoriasin was analysed using real-time
PCR and the LightCycler instrument (Roche Applied Sci-
ence, Sweden), together with the LightCycler FastStart
DNA Master SYBR Green I kit (Roche Applied Science,
Sweden), according to the manufacturer's instructions.
Primers for psoriasin [2] and β-actin [19] were as previ-
ously described. Two µl of cDNA were added to 18 µl of
PCR Master Mixture (including 3 mM of MgCl2, 0.5 mM
of primers (psoriasin and β-actin) and 2 µl of LightCy-
cler™Fast Start Master SYBR Green). The protocol con-
sisted of a 10-min denaturation step at 95°C and 40–45
cycles of amplification at 95°C for 10 seconds, 58°C (pso-
riasin) and 60°C (β-actin) for five seconds and 72°C for
eight seconds (β-actin) and 10 seconds (psoriasin) respec-
tively. After amplification, melting curves were obtained
to verify the specificity of the amplification reaction and
the products were also run on a 2% agarose gel. Quantita-
tive analysis was performed with the LightCycler software
version 3.5 (Roche Applied Science, Sweden), which esti-
mates the crossing point (CP) for each sample. The CP
values determined for psoriasin were normalised to β-
actin (endogenous control).
MTS assay
Viability in cell culture after IFN-gamma exposure was
estimated using a CellTiter 96® AQueous One Solution Cell
proliferation assay (MTS) (Promega, Madison, WI, USA),
according to the manufacturer's manual. The absorbance
at 490 nm was recorded using the Mithras LB940 Instru-
ment (Berthold Technologies).
Statistical analysis
To study the association between psoriasin expression and
viability, psoriasin-expressing cells were compared with
control cells using a one-tailed paired t-test.
Results
Suppression of psoriasin expression by IFN-gamma
We tested the effect of IFN-gamma on the induction of
psoriasin by anoikis (suspension culture), confluence and
ROS, conditions which induce psoriasin and calgranulin
B [7,20]. As depicted in Figure 1a, IFN-gamma treatment
suppressed psoriasin induction by anoikis in MCF10A
cells, as well as in HEKn cells, while it had no effect on
psoriasin induction by ROS or confluent conditions (data
not shown). We showed that, like psoriasin and calgranu-
lin B, calgranulin A is also induced by these culture condi-
tions (Figures 1b and 1c). However, we found no effect of
IFN-gamma on calgranulin A and calgranulin B protein
levels. In conclusion, we found that IFN-gamma treat-
ment suppressed psoriasin induction by anoikis in two
cell lines derived from two distinct epithelial tissues andBMC Cancer 2007, 7:205 http://www.biomedcentral.com/1471-2407/7/205
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that calgranulin A and calgranulin B were not modulated
by the treatment (Figure 1a and 1b). IFN-gamma treat-
ment had no effect on the protein levels of pro-caspase-3
(Figure 1a).
The ER-negative MDA-MB-468 breast carcinoma cell line
has previously been shown constitutively to express pso-
riasin at high levels [5]. In accordance with the effect of
IFN-gamma on psoriasin induction by anoikis, we
showed that MDA-MB-468 cells treated with IFN-gamma
also downregulate psoriasin (Figure 1d). We showed that
MDA-MB-468 cells also display a high expression of cal-
granulin A and calgranulin B. However, similar to the
findings in anoikis, the expression of calgranulin A and
calgranulin B was not influenced by IFN-gamma treat-
ment (data not shown).
Downregulation of psoriasin expression occurs at the RNA 
level
The effect of IFN-gamma treatment was measured at the
RNA level. Results of RT-PCR analyses (Figure 2) showed
that the psoriasin RNA levels were dramatically reduced
after treatment with IFN-gamma in both MDA-MB-468
and MCF10A cells. In fact, after 48 hours treatment with
IFN-gamma the psoriasin expression level was reduced to
only 0.5–2% of that of control cells. These data suggest
that the effect of IFN-gamma on psoriasin expression is
mediated at the transcriptional level.
Activation of the STAT1 signaling pathway
IFN-gamma is an important activator of STAT1 signaling
[21]. To determine whether the downregulation of psoria-
sin involved the activation of STAT1, we studied the IFN-
gamma/Jak/STAT1 pathway using antibodies against
STAT1 and phosphorylated STAT1. The induction of
STAT1 confirms the presence of the IFN-gamma receptor
and the phosphorylated form confirms an active signaling
pathway. In agreement with this, we demonstrated the
upregulation of STAT1 in MDA-MB-468 cells, HEKn cells
and MCF10A cells after 48 hours' treatment with IFN-
gamma (Figure 3a). IFN-gamma treatment led to the
phosphorylation of the STAT1 protein (Tyr-701) within a
few minutes, thus confirming an active signaling pathway
(Figure 3b).
Psoriasin mRNA levels are downregulated in response to  IFN-gamma Figure 2
Psoriasin mRNA levels are downregulated in 
response to IFN-gamma. Cells were treated 48 hours 
with 350–1000 u of IFN-gamma and total RNA was pre-
pared. Using real-time polymerase chain reaction (RT-PCR), 
mRNA level of psoriasin was downregulated in response to 
IFN-gamma in MCF10A cells (A) and in MDA-MB-468 cells 
(B). Expression data for psoriasin are presented as ratios, in 
which the expression data are normalized to an endogenous 
control (β-actin). Values obtained in control cells were 
designed as 1 and values obtained from IFN-gamma treated 
cells were normalized to this from the same run. The data 
are presented as the mean of three different runs.
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Psoriasin expression is suppressed by IFN-gamma Figure 1
Psoriasin expression is suppressed by IFN-gamma. A, 
Suspension culture of MCF10A and HEKn shows the repres-
sion of psoriasin induction when treated 48 hours with 250 
u, 500 u or 1000 u of IFN-gamma. IFN-gamma treatment had 
no effect on the protein levels of pro-caspase-3. Calgranulin 
B and calgranulin A (B) are not influenced by the IFN-gamma 
treatment. Equal amounts of protein lysate were loaded on 
the gel. C, Treatment with 75 µM H2O2 for one hour fol-
lowed by culture for 48 h in regular medium induces the 
expression of calgranulin A in MCF10A cells. 100 µg of pro-
tein lysate were loaded on the gel. D, MDA-MB-468 cells 
with the endogenous expression of psoriasin show the time-
dependent repression of psoriasin expression when treated 
24, 48 and 72 hours with 1000 u of IFN-gamma. Equal 
amounts of protein lysate were loaded on the gel. Probing 
with tubulin/GAPDH assesses the equal loading of the sam-
ples. C = cells cultured in monolayer.
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The SUM190 breast carcinoma cell line also has high
endogenous psoriasin protein levels. IFN-gamma did not
downregulate psoriasin expression in this cell line,
although the presence of the IFN-gamma receptor could
be confirmed (Figure 3a). Interestingly, IFN-gamma treat-
ment did not lead to a marked phosphorylation of the
STAT1 protein, as we observed in the MDA-MB-468 cell
line. This finding implies that STAT1 signaling is required
for the IFN-gamma-mediated suppression of psoriasin
expression (Figure 3b).
Effect of IFN-gamma on cell viability and caspase activity
In order to determine the effect IFN-gamma had on cellu-
lar viability, normal mammary epithelial MCF10A cells
were incubated with 500 u of IFN-gamma. Using the MTS
assay, we showed that cell viability was reduced by 32%
after 7 days (Figure 4).
IFN-gamma treatment and the inhibition of NFκB were
shown to have a synergistic effect on psoriasin levels (Fig-
ure 5). NFκB was blocked using a phosphorylation-defec-
tive dnIkkβ virus, which blocks the phosphorylation of
IκBα necessary for NFκB activation. Figure 5 shows that
dnIkkβ suppresses psoriasin induction and leads to the
accumulation of the NFκB inhibitor IκBα. There was no
difference in pro-caspase-3 level after dnIkkβ expression
and IFN-gamma treatment, suggesting that the reduction
in the induction of psoriasin following the expression of
dnIkkβ and IFN-gamma is not due to increased apoptosis
(Figure 5).
Increased viability in psoriasin-expressing TAC2 cells
To study the functional relevance of high psoriasin expres-
sion in mammary epithelial cells, we established a TAC2
cell line expressing psoriasin in an inducible manner
using the Tet-Off system. Several clones with low basal
and high inducible psoriasin levels were isolated (Figure
6a). We found no significant difference between the pro-
liferation of psoriasin-expressing TAC2 cells and control
TAC2 cells (data not shown). We have previously shown
an increase in the survival of psoriasin-expressing
MCF10A cells in response to ROS, compared with control
cells, and have demonstrated that this increase in survival
is likely to be mediated by the NFκB pathway. Like ROS,
IFN-gamma treatment leads to decreased viability in
mammary epithelial cells (Figure 4). To determine
whether psoriasin has an effect on cell viability after IFN-
gamma treatment, we used mammary epithelial TAC2
cells with tetracycline-inducible (Tet-Off) psoriasin
expression. Psoriasin-expressing TAC2 cells and control
IFN-gamma treatment inhibits the viability of mammary epi- thelial cells Figure 4
IFN-gamma treatment inhibits the viability of mam-
mary epithelial cells. Mammary epithelial MCF10A cells 
were treated with 500 u of IFN-gamma at seeding. Cell viabil-
ity was measured using the MTS-assay on days 3 and 7 and 
the IFN-gamma/control quotient is demonstrated. Treatment 
with IFN-gamma produced a 59.5% (day 3) and 32% (day 7) 
reduction in viability as compared to control cells. The assay 
was performed in duplicate.
0%
20%
40%
60%
80%
100%
120%
037
Duration of treatment (days)
R
a
t
i
o
 
(
I
F
N
-
g
a
m
m
a
/
 
C
o
n
t
r
o
l
 
c
e
l
l
s
)
IFN-gamma upregulates STAT1 expression and stimulates  the phosphorylation of STAT1 Figure 3
IFN-gamma upregulates STAT1 expression and 
stimulates the phosphorylation of STAT1. A, IFN-
gamma upregulates STAT1 expression in MDA-MB-468, 
SUM190, HEKn, and MCF10A cells. The upregulation of 
STAT1 confirms the presence of the IFN-gamma receptor 
(48 hours' treatment with 1000 u of IFN-gamma). Endog-
enous psoriasin expression in MDA-MB-468 is downregu-
lated by IFN-gamma treatment. However, in the SUM190 cell 
line, endogenous psoriasin expression was not affected by 
the treatment. Equal amounts of protein lysate for the differ-
ent cell lines were loaded on the gel. Tubulin assesses equal 
loading in MDA-MB-468, HEKn and MCF10A cells. GAPDH 
assesses equal loading in SUM190 cells. B, Treatment with 
1000 u of IFN-gamma led to the phosphorylation of STAT1 
five and 15 minutes after IFN-gamma treatment in MDA-MB-
468 cells, which confirms an active signaling pathway. 
Reduced phosphorylation of STAT1 was observed in the 
SUM190 cell line. 100 µg of protein lysate were loaded on 
the gel. GAPDH assesses equal loading. C control.
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TAC2 cells were treated with IFN-gamma and viability was
measured by MTS assay. The viability of the psoriasin-
expressing TAC2 cells was 15% higher than in the non-
expressing TAC2 cells when IFN-gamma was added at
seeding (p = 0.01) (Figure 6b). Interestingly, psoriasin-
expressing cells showed a resistant phenotype only when
IFN-gamma was added when cells were plated. Treatment
after cell attachment did not confer any difference in cell
viability (data not shown).
Discussion
IFN-gamma is a cytokine with diverse biological effects
mediated by a variety of responsive genes. The anti-
tumoral role for this cytokine involves both immunologic
and non-immunologic processes. IFN-gamma activates
cells in the innate immune system to proliferate and to
produce cytokines [22]. In addition, IFN-gamma may
have direct anti-proliferative and pro-apoptotic effects on
a variety of tumor cells [16]. The activation of the inter-
feron-stimulated genes (ISG) requires the activity of
STAT1 transcription factor [21]. IFN-gamma is a potent
activator of STAT1 and activated, phosphorylated STAT1
has been correlated to a good prognosis in breast cancer
[23]. IFN-gamma inhibits the cell growth of mammary
carcinoma cells and also reduces the angiogenic pheno-
type [17,18]. In metastatic breast cancer, IFN-gamma has
been shown to enhance the growth-inhibitory effects of
tamoxifen [24,25]. Moreover, a novel, promising antican-
cer drug, indole-3-carbinol (13C), was shown to increase
the expression of the IFN-gamma receptor 1 and aug-
mented the interferon responsiveness in breast cancer
cells [26]. The characterization of genes that are regulated
by IFN-gamma may therefore lead to a better understand-
ing of the mechanisms of the anti-tumor action, as well as
the improved utilization of IFN-gamma in the treatment
of breast cancer.
Psoriasin reduces sensitivity to IFN-gamma- induced cell  death Figure 6
Psoriasin reduces sensitivity to IFN-gamma- induced 
cell death. A, Incubation with (+) and without (-) tetracy-
cline in the tetracycline-responsive TAC2-tet EGFP2-psoria-
sin cell line demonstrates a significant amount of psoriasin 
expression in the absence of tetracycline. With tetracycline, 
the expression of psoriasin transcription is effectively sup-
pressed. GAPDH assesses equal loading. 100 µg of protein 
lysate were loaded on the gel. B, Mammary epithelial TAC2 
cells with tetracycline-inducible (Tet-Off) psoriasin expres-
sion (TAC2-tet EGFP2-psoriasin) demonstrate 15% higher 
viability in psoriasin-expressing cells (Tet-) than non-express-
ing (Tet+) when IFN-gamma (1000 u- 2000 u) is added at 
seeding (* p = 0.01, one-tailed paired t-test). Viability was 
measured by MTS assay on day 3 and the quotient IFN-
gamma/control is demonstrated. The assay was performed in 
duplicate.
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IFN-gamma and the inhibition of NFκB suppress anoikis- induced psoriasin expression Figure 5
IFN-gamma and the inhibition of NFκB suppress 
anoikis-induced psoriasin expression. 500 u of IFN-
gamma suppresses the psoriasin expression induced by 
anoikis for 48 hours either by itself or in combination with 
dnIkkβ-virus in MCF10A cells. Neither infection with the dif-
ferent adenoviruses nor the IFN-gamma had any effect on 
the protein levels of pro-caspase-3. The function of the virus 
was verified by the accumulation of the IκBα protein. Tubulin 
assesses equal loading. C control.
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Psoriasin, calgranulin A and calgranulin B are calcium-
binding proteins with diverse biological functions. They
have a high degree of structural and sequence homology
and all three proteins, and psoriasin in particular, are
highly expressed in DCIS and in the hyperproliferative
skin disorder, psoriasis. We recently showed, by the hier-
archical clustering of S100 gene expression in 22 breast
cancer SAGE libraries, that one group with a distinguisha-
ble S100 gene expression profile was characterized by the
high concomitant expression of psoriasin, calgranulin A
and calgranulin B [27]. We are therefore focusing our
interest not only on psoriasin but also on all three pro-
teins.
We have now shown that psoriasin induction in MCF10A
cells in anoikis (suspension culture) was suppressed after
IFN-gamma exposure, at both the protein and mRNA
level. The same effect was observed in the HEKn cell line,
suggesting that this effect was not tissue specific. The
MDA-MB-468 breast cancer cell line, which has endog-
enously produced psoriasin expression, also reduced the
psoriasin expression level after IFN-gamma treatment.
The cells treated with IFN-gamma displayed the upregula-
tion and phosphorylation of STAT1, which indicates an
active signaling pathway. These findings suggest that IFN-
gamma mediates its suppressive effect on psoriasin tran-
scription by activating the STAT1 signaling pathway. This
conclusion is further supported by the reduced phospho-
rylation of the STAT1 protein after IFN-gamma treatment
in the SUM190 cell line, where the high endogenous
expression of psoriasin was not affected by the IFN-
gamma treatment.
We have previously reported the increased survival of pso-
riasin-expressing cells after ROS treatment [7]. We now
also show the increased viability in psoriasin-expressing
mammary TAC2 cells after IFN-gamma treatment, which
inhibits the cell growth of mammary carcinoma cells.
High-grade comedo DCIS tumors demonstrate high
apoptosis rates [28] and surviving tumor cells are also
likely to be relatively more resistant to apoptosis. ROS
thus lead to the endogenous production of psoriasin,
which may contribute to apoptosis resistance in DCIS and
psoriasis. The cytoprotective role of psoriasin in IFN-
gamma-induced cell death is in line with the reported
anti-apoptotic role of NFκB in several cell types, such as
the protection from Tumor Necrosis Factor-α-induced
apoptosis [29]. The increased viability seen in psoriasin-
expressing cells could therefore be mediated through an
NFκB-dependent pathway, which is supported by our
data.
Interestingly, although all three S100 proteins are
expressed in the MDA-MB-468 cancer cell line and in the
normal epithelial cell lines in anoikis, IFN-gamma treat-
ment had no effect on the expression levels of calgranulin
A and calgranulin B. This may indicate that IFN-gamma
interferes with signals that specifically modulate psoriasin
expression.
In addition to the induction of psoriasin expression seen
in anoikis, we have previously demonstrated the upregu-
lation of psoriasin and calgranulin B in mammary epithe-
lial cells (MCF10A) and keratinocytes (HEKn) in response
to several other differentiation-promoting stimuli, such as
an increase in extracellular calcium and confluent condi-
tions [20]. We have also shown that psoriasin and calgran-
ulin B are induced by ROS [7]. We now also show that
calgranulin A is induced by ROS, which supports the
assumption that these three S100 proteins share, at least
in part, common signaling pathways in breast cancer. Our
hypothesis is that, in all the conditions that induce psoria-
sin, calgranulin A and calgranulin B expression, ROS are
produced. Accordingly, we have demonstrated the sup-
pression of psoriasin and calgranulin B by the antioxi-
dants Bcl-2 and N-acetyl-cysteine (NAC). However, we
only observed the suppression of psoriasin by IFN-gamma
in the anoikis condition, suggesting that the IFN-gamma-
mediated signals implicated in psoriasin expression may
only be present in anoikis and not in the other differenti-
ation-promoting conditions.
We hypothesise that psoriasin is induced in anoikis by
other stimuli and not only because of the presence of
ROS. This would explain the massive induction seen in
anoikis as compared with the other inducing conditions
[3]. The finding that IFN-gamma suppresses psoriasin
induction in anoikis lead to the hypothesis that the loss of
adhesion signaling may contribute to the high psoriasin
expression. Furthermore, the viability assay suggests that
psoriasin expression may be related to the attachment of
cells to the extracellular matrix; we observed that viability
was higher in psoriasin-expressing cells when cells were
treated with IFN-gamma at seeding compared with treat-
ment following cell attachment. Attempts to identify the
adhesion signals that interfere with psoriasin expression
are currently ongoing.
The finding that psoriasin is downregulated by IFN-
gamma has interesting clinical implications. IFN-gamma
and STAT1 have previously been shown negatively to reg-
ulate angiogenesis. Recently, IFN-gamma was shown to
suppress several of the angiogenic effects of VEGF [30].
We have previously shown that the downregulation of
endogenous psoriasin in MDA-MB-468 cells led to the
corresponding downregulation of VEGF and decreased
tumour size [9]. The importance of psoriasin in mediating
the anti-angiogenic properties of IFN-gamma remains to
be determined.BMC Cancer 2007, 7:205 http://www.biomedcentral.com/1471-2407/7/205
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Conclusion
We report the suppression of psoriasin by IFN-gamma in
two cell lines derived from two different normal epithelial
tissues and in the ER-negative MDA-MB-468 breast carci-
noma cell line. Our data implies that IFN-gamma medi-
ates its suppressive effect on psoriasin transcription by
activating the STAT1 signaling pathway. Psoriasin-
expressing mammary epithelial cells showed increased
viability after IFN-gamma exposure compared with nor-
mal cells.
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